162 related articles for article (PubMed ID: 35770457)
41. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.
Meyer A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2021 Aug; 54(3):302-311. PubMed ID: 34162011
[TBL] [Abstract][Full Text] [Related]
42. Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study.
Winter RW; Larsen MD; Magnussen B; Friedman S; Kammerlander H; Nørgård BM
Reprod Toxicol; 2017 Dec; 74():219-223. PubMed ID: 29080667
[TBL] [Abstract][Full Text] [Related]
43. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.
Dulai PS; Thompson KD; Blunt HB; Dubinsky MC; Siegel CA
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1443-51; quiz e88-9. PubMed ID: 24462626
[TBL] [Abstract][Full Text] [Related]
44. Mortality Associated With Development of Squamous Cell Cancer in Patients With Inflammatory Bowel Diseases Receiving Treatment With Thiopurines.
Khan N; Lee H; Trivedi C; Kavani H; Medvedeva E; Xie D; Lewis JD; Yang YX
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2262-2268. PubMed ID: 30853615
[TBL] [Abstract][Full Text] [Related]
45. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea.
Hong SN; Kim HJ; Kim KH; Han SJ; Ahn IM; Ahn HS
Aliment Pharmacol Ther; 2017 Jan; 45(2):253-263. PubMed ID: 27933686
[TBL] [Abstract][Full Text] [Related]
46. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
47. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
[TBL] [Abstract][Full Text] [Related]
48. The Severity of Herpes Zoster in Inflammatory Bowel Disease Patients Treated With Anti-TNF Agents.
Khan N; Trivedi C; Shah Y; Patel D; Lewis J; Yang YX
Inflamm Bowel Dis; 2018 May; 24(6):1274-1279. PubMed ID: 29522099
[TBL] [Abstract][Full Text] [Related]
49. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.
Nyboe Andersen N; Pasternak B; Basit S; Andersson M; Svanström H; Caspersen S; Munkholm P; Hviid A; Jess T
JAMA; 2014 Jun; 311(23):2406-13. PubMed ID: 24938563
[TBL] [Abstract][Full Text] [Related]
50. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.
Rungoe C; Basit S; Ranthe MF; Wohlfahrt J; Langholz E; Jess T
Gut; 2013 May; 62(5):689-94. PubMed ID: 22961677
[TBL] [Abstract][Full Text] [Related]
51. Inflammatory Bowel Disease and Risk of Adverse Pregnancy Outcomes.
Boyd HA; Basit S; Harpsøe MC; Wohlfahrt J; Jess T
PLoS One; 2015; 10(6):e0129567. PubMed ID: 26083614
[TBL] [Abstract][Full Text] [Related]
52. Sex-dimorphic adverse drug reactions to immune suppressive agents in inflammatory bowel disease.
Zelinkova Z; Bultman E; Vogelaar L; Bouziane C; Kuipers EJ; van der Woude CJ
World J Gastroenterol; 2012 Dec; 18(47):6967-73. PubMed ID: 23322995
[TBL] [Abstract][Full Text] [Related]
53. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring-A nationwide cohort study.
Friedman S; Larsen MD; Magnussen B; Jølving LR; de Silva P; Nørgård BM
Reprod Toxicol; 2017 Oct; 73():196-200. PubMed ID: 28844800
[TBL] [Abstract][Full Text] [Related]
54. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
[TBL] [Abstract][Full Text] [Related]
55. Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children.
Meyer A; Rios P; Drouin J; Weill A; Carbonnel F; Dray-Spira R
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2679-2681.e5. PubMed ID: 36064096
[No Abstract] [Full Text] [Related]
56. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study.
Vos AC; Bakkal N; Minnee RC; Casparie MK; de Jong DJ; Dijkstra G; Stokkers P; van Bodegraven AA; Pierik M; van der Woude CJ; Oldenburg B; Hommes DW;
Inflamm Bowel Dis; 2011 Sep; 17(9):1837-45. PubMed ID: 21830262
[TBL] [Abstract][Full Text] [Related]
57. Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease.
Kirchgesner J; Desai RJ; Beaugerie L; Schneeweiss S; Kim SC
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):314-324.e16. PubMed ID: 33387667
[TBL] [Abstract][Full Text] [Related]
58. Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease.
Andersson P; Karling P
Ups J Med Sci; 2022; 127():. PubMed ID: 35140875
[TBL] [Abstract][Full Text] [Related]
59. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
[TBL] [Abstract][Full Text] [Related]
60. Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.
Korzenik J; Larsen MD; Nielsen J; Kjeldsen J; Nørgård BM
Aliment Pharmacol Ther; 2019 Aug; 50(3):289-294. PubMed ID: 31267570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
